Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
22,058
Total Claims
$4.0M
Drug Cost
484
Beneficiaries
$8,222
Cost/Patient
Risk Score Breakdown 21/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+483%
Cost per patient vs peers
$8,222 vs $1,411 avg
+125%
Brand preference vs peers
23.9% vs 10.6% avg
Brand vs Generic
Brand: 5,155 claims · $3.4M
Generic: 16,415 claims · $569K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Icosapent Ethyl | 1,803 | $995K |
| Dapagliflozin Propanediol | 335 | $306K |
| Sitagliptin Phos/Metformin Hcl | 311 | $229K |
| Denosumab | 129 | $220K |
| Diclofenac Epolamine | 313 | $215K |
| Lipase/Protease/Amylase | 125 | $180K |
| Budesonide/Formoterol Fumarate | 240 | $120K |
| Cyclosporine | 119 | $119K |
| Diclofenac Sodium | 453 | $112K |
| Tenofovir Alafenamide | 46 | $77K |
| Mirabegron | 74 | $66K |
| Lipase/Protease/Amylase | 30 | $61K |
| Linaclotide | 73 | $50K |
| Apixaban | 67 | $47K |
| Empagliflozin | 52 | $45K |
Prescribing Profile
Patient Profile
74
Avg Age
57%
Female
1.10
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data